Copper-Doped Carbon Quantum Dots with Near-Infrared Photothermal and Photodynamic Performance for in vitro Dual-Modal Phototherapeutic Eradication of Embryonal Carcinoma Cells
International Journal of Nanomedicine · 2026-11 · Volume 21 · 1-12
DOI: 10.2147/ijn.s657849 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-11. Verfasst von Mohamad Mahani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Shahid Bahonar University of Kerman, Kerman, 7616913439, Iran. Hauptthemen laut MEDLINE: Copper, Carbon Quantum Dots, Photochemotherapy, Photosensitizing Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
The clinical efficacy of conventional photodynamic therapy (PDT) remains constrained by limited light penetration in deep tissue and suboptimal ROS yields of traditional photosensitizers. This study aimed to develop biocompatible copper-doped carbon quantum dots (NIR-CQDs) exhibiting near-infrared (NIR) absorption to achieve dual photothermal and photodynamic ablation of malignant cells within the biological transparency window. Materials and methods NIR-CQDs were synthesized via a facile, one-step hydrothermal method. The nanostructures were characterized by UV-Vis-NIR absorption and fluorescence spectroscopy. Photothermal performance and thermal stability were evaluated under continuous 808 nm laser irradiation. ROS quantum yield was quantified using 1,3-diphenylisobenzofuran (DPBF) as a chemical probe against methylene blue. Light-activated in vitro cytotoxicity were systematically assessed in human NCCIT embryonal carcinoma cells. A reactive oxygen species (ROS) quenching assay utilizing reduced glutathione (GSH) was employed to evaluate the relative contributions of localized hyperthermia and oxidative pathways.
Results
The synthesized NIR-CQDs exhibited an average hydrodynamic size of ~5 nm with NIR absorption extending near 780 nm. The NIR-CQDs demonstrated ROS generation ([Formula: see text] = 6.96%), alongside photothermal conversion that elevated aqueous temperatures to 62 °C under 808 nm illumination, displaying stable photothermal cycling. In vitro evaluations demonstrated negligible dark cytotoxicity in NCCIT cells across tested concentrations. Upon 808 nm NIR irradiation, NIR-CQDs mediated substantial phototoxicity, reducing cancer cell viability to ~35% (p Conclusion A carbon-based NIR-CQD nanoplatform was developed, integrating ROS generation with NIR-driven photothermal conversion. The combination of photodynamic and photothermal effects provides an effective approach for cell killing in vitro, highlighting the potential of these NIR-CQDs for NIR-activated cancer phototherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Shahid Bahonar University of Kerman, Kerman, 7616913439, Iran.
- Department of Chemistry, Faculty of Chemistry & Chemical Engineering, Graduate University of Advanced Technology, Kerman, 7631818356, Iran.
ORCID-Profile: Mohamad Mahani
Zitieren
APA
Mahani, M., & Montazer, L. (2026). Copper-Doped Carbon Quantum Dots with Near-Infrared Photothermal and Photodynamic Performance for in vitro Dual-Modal Phototherapeutic Eradication of Embryonal Carcinoma Cells. International Journal of Nanomedicine, Volume 21, 1-12. https://doi.org/10.2147/ijn.s657849
Vancouver
Mahani M, Montazer L. Copper-Doped Carbon Quantum Dots with Near-Infrared Photothermal and Photodynamic Performance for in vitro Dual-Modal Phototherapeutic Eradication of Embryonal Carcinoma Cells. International Journal of Nanomedicine. 2026;Volume 21:1-12. doi:10.2147/ijn.s657849
BibTeX
@article{Mahani2026,
author = {Mahani, Mohamad and Montazer, Leila},
title = {Copper-Doped Carbon Quantum Dots with Near-Infrared Photothermal and Photodynamic Performance for in vitro Dual-Modal Phototherapeutic Eradication of Embryonal Carcinoma Cells},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--12},
doi = {10.2147/ijn.s657849}
}
EUVIMED